Robert W. Baird Boosts Agilent Technologies (NYSE:A) Price Target to $165.00

Agilent Technologies (NYSE:A) had its price objective increased by equities researchers at Robert W. Baird from $142.00 to $165.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price target points to a potential upside of 6.78% from the company’s current price.

Several other research analysts also recently commented on the stock. Evercore ISI increased their price objective on shares of Agilent Technologies from $128.00 to $140.00 and gave the company an “in-line” rating in a report on Tuesday, October 7th. TD Cowen boosted their target price on Agilent Technologies from $150.00 to $162.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. JPMorgan Chase & Co. increased their price target on Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Barclays raised their price target on Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Finally, Bank of America increased their target price on Agilent Technologies from $150.00 to $165.00 and gave the company a “neutral” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $161.08.

Agilent Technologies Trading Down 1.7%

A stock opened at $154.52 on Tuesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. Agilent Technologies has a 1-year low of $96.43 and a 1-year high of $160.27. The business has a 50 day simple moving average of $141.36 and a two-hundred day simple moving average of $126.23. The company has a market capitalization of $43.81 billion, a price-to-earnings ratio of 36.27, a PEG ratio of 4.67 and a beta of 1.29.

Agilent Technologies (NYSE:A) last released its earnings results on Monday, November 24th. The medical research company reported $1.59 EPS for the quarter, topping the consensus estimate of $1.58 by $0.01. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the previous year, the firm earned $1.46 earnings per share. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS. Research analysts anticipate that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Insider Activity

In related news, CEO Padraig Mcdonnell sold 911 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $143.24, for a total transaction of $130,491.64. Following the completion of the sale, the chief executive officer directly owned 32,058 shares of the company’s stock, valued at approximately $4,591,987.92. This trade represents a 2.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Institutional Trading of Agilent Technologies

Institutional investors and hedge funds have recently modified their holdings of the stock. Brighton Jones LLC grew its stake in Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after purchasing an additional 270 shares in the last quarter. Cetera Investment Advisers grew its position in shares of Agilent Technologies by 8.1% during the 1st quarter. Cetera Investment Advisers now owns 36,267 shares of the medical research company’s stock worth $4,243,000 after buying an additional 2,723 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Agilent Technologies by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 236,725 shares of the medical research company’s stock valued at $27,692,000 after buying an additional 11,079 shares during the period. LPL Financial LLC raised its holdings in shares of Agilent Technologies by 3.8% in the first quarter. LPL Financial LLC now owns 121,147 shares of the medical research company’s stock valued at $14,172,000 after acquiring an additional 4,468 shares in the last quarter. Finally, Mackenzie Financial Corp raised its holdings in shares of Agilent Technologies by 141.5% in the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock valued at $109,481,000 after acquiring an additional 548,344 shares in the last quarter. Institutional investors own 87.41% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.